HOHitoshi Ohmori

Hitoshi Ohmori

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hitoshi Ohmori has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of Parameters for Cancer-Induced Sarcopenia in Patients Autopsied after Death from Colorectal Cancer

    by Hitoshi Ohmori, Isao Kawahara, Takuya Mori, Shota Nukaga, Yi Luo, Shingo Kishi, Rina Fujiwara-Tani, Shiori Mori, Kei Goto, Takamitsu Sasaki, et al.

    Cachexia frequently occurs in cancer patients and is correlated with reduced therapeutic responsiveness and poor prognosis. Although skeletal muscle atrophy is an important factor related to cachexia, biomarkers for its early diagnosis are not yet definitive. In this study, weight loss, body mass index, skeletal muscle index (SMI), serum carcinoembryonic antigen, serum tumor necrosis factor (TNF)-α, serum interleukin (IL)-6, serum high mobility group box (HMGB)-1, and SDS-soluble myosin light chain 1 (SDS-MYL1) of the psoas muscle were examined in 8 autopsied cases of death from colorectal cancer (CRC) as biomarkers of cachexia. SDS-MYL1 was positively correlated to SMI and TNF-α was negatively correlated, but the other factors did not show any correlations with SMI. Multivariate analysis showed that of the 3 cytokines, TNF-α and HMGB1 were correlated with SMI. Furthermore, when the biochemical skeletal muscle maturation marker, SDS-MYL1, was compared with serum cytokines, TNF-α and HMGB1 were negatively correlated but IL-6 was not. In multivariate analysis, only TNF-α was associated with SDS-MYL1. A positive correlation was found between TNF-α and HMGB1. These findings suggest that since TNF-α was inversely correlated with SMI and SDS-MYL1, TNF-α is a serum marker of skeletal muscle atrophy in CRC. Moreover, SDS-MYL1 might be established as a biomarker linked to clinical sarcopenia in experiments in vitro and in vivo.


  • Open Access

    Expression of long‑chain fatty acid receptor GPR40 is associated with cancer progression in colorectal cancer: A retrospective study

    by Chie Nakashima, Kishi Shingo, Rina Fujiwara‑Tani, Yi Luo, Isao Kawahara, Kei Goto, Takamitsu Sasaki, Kiyomu Fujii, Hitoshi Ohmori, Hiroki Kuniyasu

    An increased risk of colorectal cancer (CRC) is associated with a western style diet, particularly hyperlipidemia. The expression of G‑protein coupled receptor 40 (GPR40), a membrane‑bound receptor for long‑chain fatty acids (LCFAs), was examined in 36 cases of subserosal‑invading CRC and compared with clinicopathological parameters as well as triglyceride (TG) and low‑density lipoprotein (LDL) levels in the blood. All patients with CRC expressed GPR40, which was positively associated with blood TG levels (P<0.0001) but not with blood LDL levels. GPR40 expression was positively associated with nodal metastasis, distant metastasis (particularly to the liver), stage and poor prognosis. Patients with high GPR40 expression and high TG levels had comparatively worse survival outcomes compared with patients with low GPR40 expression and low TG levels. The results of the present study suggest that activation of GPR40 may be associated with the progression and prognosis of CRCs. High levels of GPR40 and/or concurrent high levels of GPR40 and TG may be a risk for CRC progression.


  • Open Access

    Fatty acids inhibit anticancer effects of 5-fluorouracil in mouse cancer cell lines

    by Eriko Tanabe, Misaho Kitayoshi, Kiyomu Fujii, Hitoshi Ohmori, Yi Luo, Yui Kadochi, Shiori Mori, Rina Fujiwara, Yukiko Nishiguchi, Takamitsu Sasaki, et al.

    The present study investigated the effects of two major dietary fatty acid components, linoleic acid (LA) and elaidic acid (EA), on the antitumor effects of 5-fluorouracil (5‑FU) in the LL2, CT26 and CMT93 mouse cancer cell lines. Concurrent treatment with LA and 5‑FU elicited a decreased cell viability compared with treatment with 5‑FU alone. In addition, increased inhibition of growth was observed following concurrent treatment with EA and 5‑FU. Sequential treatment of LA followed by 5‑FU abrogated the anticancer effects of 5‑FU, and treatment with EA followed by 5‑FU increased cancer cell growth in addition to abrogating the anticancer effects of 5‑FU. The expression of the stem cell markers CD133 and nucleostemin (NS) increased in all three cell lines treated concurrently with 5‑FU and either LA or EA when compared with cells treated with 5‑FU alone. Aldehyde dehydrogenase activity in the cancer stem cells (CSCs), in response to concurrent treatment with 5‑FU and either LA or EA, was increased compared with 5‑FU treatment alone. 5‑FU inhibited the growth of CT26 tumors, but co‑treatment with either LA or EA abrogated this effect. NS‑positive CSCs were more abundant in CT26 tumors treated with 5‑FU and either LA or EA compared with those treated with 5‑FU alone. The results of the present study suggested that, rather than altering the sensitivity of cancer cells to 5‑FU, LA and EA may promote the survival of CSCs. The results indicated that dietary composition during chemotherapy is an important issue.


  • Serum CD10 is associated with liver metastasis in colorectal cancer

    by Takamitsu Sasaki, Hiroki Kuniyasu, Yi Luo, Rina Fujiwara, Misaho Kitayoshi, Eriko Tanabe, Daisuke Kato, Satoshi Shinya, Kiyomu Fujii, Hitoshi Ohmori, et al.


  • Open Access

    Co‐treatment with deoxycholic acid and azoxymethane accelerates secretion of HMGB1 in IEC6 intestinal epithelial cells

    by K. Fujii, Y. Luo, T. Sasahira, A. Denda, H. Ohmori, H. Kuniyasu

    Objectives:  High‐mobility group box 1 (HMGB1) is a nuclear protein that acts as a ligand of the receptor for advanced glycation end products (RAGE) and its expression enhances progression of cancer. However, the mechanism underlying HMGB1 secretion is still unclear. In this study, we examined the effect of deoxycholic acid (DCA), a promoter of colon carcinogenesis, on HMGB1 secretion.Materials and Methods:  We used an in vitro transformation model comprised of IEC6 intestinal epithelial cells treated with azoxymethane (AOM) and/or DCA. HMGB1 expression and secretion were examined by Western and Northern blot analyses, and ELISA. Intracellular translocation of HMGB1 was examined by protein fractionation.Results:  AOM + DCA‐treated IEC6 cells showed upregulation of HMGB1 mRNA expression and increased level of HMGB1 protein in culture medium, but decreased level of HMGB1 protein in the nucleus. AOM + DCA treatment increased level of histone H4 acetylation, which induced translocation of HMGB1 from the nucleus to the cytoplasm and increased HMGB1 secretion. Leptomycin B inhibited extranuclear translocation and secretion of the HMGB1 protein.Conclusion:  These findings suggest that DCA affects intracellular localization and secretion of HMGB1.


  • Enzyme release assay of human NK cell activity using β-galactosidase-expressing K562 target cell line

    by Hitoshi Ohmori, Hidenori Ikeda, Takahiro Tanigawa, Toshiyuki Takai, Masaki Hikida


  • In vitro antigen-specific IgE response is refractory to suppression by interferon-γ

    by Hitoshi Ohmori, Masaki Hikida, Ken-Ichi Haruna, Tatsuya Kishimoto